Restricted accessBrief reportFirst published online 2011-10
Human-Leukocyte Antigen Class I Cw 1502 and Class II DR 0301 Genotypes Are Associated with Resistance to Severe Acute Respiratory Syndrome (SARS) Infection
One-hundred and thirty confirmed cases of severe acute respiratory syndrome (SARS) were recruited to evaluate their anti-SARS-coronavirus (CoV) antibody status and human leukocyte antigen (HLA) types in September 2006, 3 y after the SARS outbreaks in Taiwan. Western blot assay showed that 6.9% of participants still had anti-spike and anti-nucleocapside antibodies. A case-control study of the association of HLA with SARS revealed that the HLA-Cw1502 and DR0301 alleles conferred resistance against SARS infection (p<0.05).
Get full access to this article
View all access options for this article.
References
1.
BlackwellJM, JamiesonSE, BurgnerD. HLA and infectious diseases. Clin Microbiol Rev, 2009; 22:370–385table of contents.
2.
BlaisME, DongT, Rowland-JonesS. HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?Immunology, 2011; 133:1–7.
3.
BreitburdF, RamozN, SalmonJ, OrthG. HLA control in the progression of human papillomavirus infections. Semin Cancer Biol, 1996; 7:359–371.
4.
ChangMS, LuYT, HoSTet al.Antibody detection of SARS-CoV spike and nucleocapsid protein. Biochem Biophys Res Commun, 2004; 314:931–936.
5.
ChenYM, LiangSY, ShihYPet al.Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. J Clin Microbiol, 2006; 44:359–365.
6.
ChiuRW, ChimSS, LoYM. Molecular epidemiology of SARS—from Amoy Gardens to Taiwan. N Engl J Med, 2003; 349:1875–1876.
7.
DuL, ZhaoG, LiL, HeY, ZhouY, ZhengBJ, JiangS. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun, 2009; 384:486–490.
8.
HamedNA, HanoAF, RaoufHA, GamalM, EissaM. Relationship between HLA-DRB1*0101, DRB1*0301 alleles and interleukin-12 in haemophilic patients and hepatitis C virus positive hepatocellular carcinoma patients. Egypt J Immunol, 2003; 10:17–26.
9.
HarcourtG, HellierS, BunceMet al.Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat, 2001; 8:174–179.
10.
HondaK, ZhengN, MurakoshiHet al.Selection of escape mutant by HLA-C-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication. Eur J Immunol, 2011; 41:97–106.
IdaliF, WikenM, WahlstromJ, MellstedtH, EklundA, RabbaniH, GrunewaldJ. Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J, 2006; 27:451–459.
13.
IsraniN, GoswamiR, KumarA, RaniR. Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India. PLoS One, 2009; 4:e8023.
14.
JinDY, ZhengBJ. Roles of spike protein in the pathogenesis of SARS coronavirus. Hong Kong Med J, 2009; 15,Suppl 2:37–40.
15.
KondoE, AkatsukaY, KuzushimaKet al.Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood, 2004; 103:630–638.
16.
LeslieA, MatthewsPC, ListgartenJet al.Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol, 2010; 84:9879–88.
17.
LinM, TsengHK, TrejautJAet al.Association of class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet, 2003; 4:9.
18.
LinY, ShenX, YangRFet al.Identification of an epitope of SARS-coronavirus nucleocapsid protein. Cell Res, 2003; 13:141–145.
19.
NewportMJ, GoetghebuerT, WeissHA, WhittleH, SiegristCA, MarchantA. Genetic regulation of immune responses to vaccines in early life. Genes Immun, 2004; 5:122–129.
20.
NgMH, LauKM, LiLet al.Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis, 2004; 190:515–518.
21.
OvsyannikovaIG, JacobsonRM, VierkantRA, JacobsenSJ, PankratzVS, PolandGA. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol, 2004; 65:1506–1515.
22.
PollackMS, RichRR. The HLA complex and the pathogenesis of infectious diseases. J Infect Dis, 1985; 151:1–8.
23.
PospelovLE. [HLA-D/DR-locus: its structure, function and role in infectious diseases]Zh Mikrobiol Epidemiol Immunobiol, 1984; 14–20.
24.
ReijonenH, KwokWW. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods, 2003; 29:282–288.
25.
ShankarkumarU, GhoshK, BadakereS, MohantyD. Novel HLA class I alleles associated with Indian leprosy patients. J Biomed Biotechnol, 2003; 2003:208–211.
26.
ThioCL, GaoX, GoedertJJet al.HLA-Cw*04 and hepatitis C virus persistence. J Virol, 2002; 76:4792–4797.
27.
ThioCL, ThomasDL, GoedertJJet al.Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis, 2001; 184:16–21.
28.
ThorsbyE. The human major histocompatibility system. Transplant Rev, 1974; 18:51–129.
29.
van LierRA, ten BergeIJ, GamadiaLE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol, 2003; 3:931–939.
30.
YanK, TanW, WangH, WangY, ZhangX, LiY, RuanL. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice. Viral Immunol, 2009; 22:57–66.
31.
ZhangX, WangJ, WenKet al.Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening. Viral Immunol, 2009; 22:407–415.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
